Healthcare entity
NovoCure is most often covered alongside Amgen, which appears in 1 of these 2 stories. They are better corroborated than the beat average, carrying 10.5 original sources each against 3.5 for the same window. Across a 122-day span, the pace is roughly 0.1 stories per week.
Last mentioned: Jun 28, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
NovoCure is most often covered alongside Amgen, which appears in 1 of these 2 stories. They are better corroborated than the beat average, carrying 10.5 original sources each against 3.5 for the same window. Across a 122-day span, the pace is roughly 0.1 stories per week. The average consequence score is 6, matching the 6 beat baseline for this window. Coverage clusters in market-trends, which accounts for 1 of those 2, with the remainder spread across 1 other category. NovoCure appears in 2 tracked Healthcare stories published from February 27, 2026 through June 28, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 614 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering NovoCure. Shared-story counts are live from our verified record — not editorial picks.
Amgen and NovoCure represent two extremes in healthcare delivery: a wholesale-dependent drug giant and a patient-centric device innovator. The comparison reveals how direct-to-patient models are reshaping oncology treatment accessibility and reimbursement dynamics.
The fourth quarter of 2025 revealed a decisive shift in the healthcare technology sector toward AI-integrated diagnostics and high-margin specialized therapies. Leading the charge, Butterfly Network reported record revenue growth driven by its AI-embedded strategy, while Solventum navigated its post-spin-off stabilization phase with resilient organic growth.
NovoCure is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
